Recombinant Mouse Integrin alpha 3 beta 1/VLA-3 Protein, CF

WhenCultrex® Mouse Laminin-I (Catalog # 3400-010-01) is coated at 2 µg/mL,Recombinant Integrin alpha 3 beta 1/VLA-3 (Catalog # 9374-A3) binds with an ED50 = 150-900 ng/mL.

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse Integrin alpha 3 beta 1/VLA-3 Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Cultrex® Mouse Laminin I (Catalog # 3400-010-01) is coated at 2 µg/mL, Recombinant alpha 3 beta 1/VLA-3 binds with an
  ED₅₀ = 150-900 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived mouse Integrin alpha 3 beta 1/VLA-3 protein
  

  Mouse Integrin alpha 3 (Phe33-Glu993) Accession # Q62470-1	His-Pro	GGGSGGGS	Acidic Tail	6-His tag
  Mouse Integrin beta 1 (Gln21-Asp728) Accession # P09055-1	His-Pro	GGGSGGGS	Basic Tail
  N-terminus				C-terminus

• Accession #: Q62470-1 (Integrin alpha 3) & P09055-1 (Integrin beta 1)
• N-terminal Sequence: Phe33 (Integrin alpha 3) & No results obtained. Gln21 inferred from enzymatic pyroglutamate treatment revealing Thr22 (Integrin beta 1)
• Structure / Form: Noncovalently-linked heterodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 116 kDa (Integrin alpha 3) & 86 kDa (Integrin beta 1).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 102-163 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse Integrin alpha 3 beta 1/VLA-3 Protein, CF

• Integrin alpha 3 beta 1
• VLA3
• VLA-3

Background

Integrin alpha 3 beta 1, also known as VLA-3 (Very Late Antigen 3), is a member of the integrin family, beta 1 subfamily, of cell membrane adhesion molecules (1-3). It is a non-covalent heterodimer composed of two type I transmembrane glycoprotein subunits, a 130-150 kDa alpha 3 (CD49c) subunit and a 130-140 kDa beta 1 (CD29) subunit. Integrin alpha 3 only associates with the beta 1 subunit. It is synthesized as a 1051 amino acid (aa) precursor that undergoes proteolytic cleavage to generate a disulfide-linked 110 kDa, 842 aa extracellular heavy chain and a 30 kDa, 176 aa TM/cytoplasmic light chain (1, 4, 5, 6). The heavy chain contains seven 60 aa repeats that fold into a propeller-like structure (7). Sequences involving the first three repeats are associated with ligand binding (1). Mouse alpha 3 heavy chain is 88% aa identical to human heavy chain. Unlike the alpha 3 subunit, the mouse beta 1 subunit does not undergo proteolytic cleavage (8). The molecule contains a 708 aa extracellular region, a 23 aa TM segment, and a 47 aa cytoplasmic domain. The extracellular region contains one von Willebrand factor-like A domain and four cysteine-rich repeats. Mouse beta 1 extracellular domain shares 93% and 98% aa sequence identity with human and rat beta 1, respectively. Integrin alpha 3 beta 1 is known to bind fibronectin, collagen, and laminin-1, 5, 8, 10 and 11 (1). It also binds tetraspanins such as CD9, CD63 and CD151. CD151 binding may actually stabilize it, enabling it to bind to additional factors (9).

1. Tsuji, T. et al. (2004) J. Membr. Biol. 200:115.
2. Gu, J. and N. Taniguchi (2004) Glycoconj. J. 21:9.
3. Kreidberg, J.A. (2000) Curr. Opin. Cell Biol. 12:548.
4. Takada, Y. et al. (1991) J. Cell. Biol. 115:257.
5. de Melker, A.A. et al. (1997) Lab. Invest. 76:547.
6. Krokhin, O.V. et al. (2003) Biochemistry 42:12950.
7. Springer, T.A. (2002) Curr. Opin. Struct. Biol. 12:802.
8. Argraves, W.S. et al. (1987) J. Cell Biol. 105:1183.
9. Nishiuchi, R. et al. (2005) Proc. Natl. Acad. Sci. USA 102:1939.

Publications for Integrin alpha 3 beta 1/VLA-3 (9374-A3)(2)

Publications using 9374-A3

• C Cegarra, B Cameron, C Chaves, T Dabdoubi, TM Do, B Genêt, V Roudières, Y Shi, P Tchepikoff, D Lesuisse An innovative strategy to identify new targets for delivering antibodies to the brain has led to the exploration of the integrin family PLoS ONE, 2022-09-15;17(9):e0274667. 2022-09-15 [PMID: 36108060] (ELISA Capture, Mouse)
• M Brehs, AJG Pötgens, J Steitz, K Thewes, J Schwarz, AC Conibear, M Bartneck, F Tacke, CFW Becker Synthetic integrin-binding immune stimulators target cancer cells and prevent tumor formation Sci Rep, 2017-12-14;7(1):17592. 2017-12-14 [PMID: 29242512] (Surface Plasmon Resonance, Mouse)

Bioinformatics

• Uniprot:
  • Q62470-1 (Integrin alpha 3) & P09055-1 (Integrin beta 1)()